Wagner R, Cissewski K, Rosenkranz M, Hayatghebi S, Reinwein D
Abteilung für Klinische Endokrinologie, Medizinische Klinik und Poliklinik, Universität Essen.
Dtsch Med Wochenschr. 1993 Nov 26;118(47):1709-13. doi: 10.1055/s-2008-1059506.
Serum interleukin-2 receptor (IL-2R) concentrations were compared in 55 patients with thyrotoxicosis (14 men, 41 women, mean age 43.5 +/- 17 years), 18 patients with Hashimoto's thyroiditis (5 men, 13 women, mean age 47 +/- 15 years) and 28 healthy subjects (12 men, 16 women, mean age 30 +/- 10 years). The patients with thyrotoxicosis were divided into three groups depending on the activity or stage of the disease: 17 patients with florid untreated hyperthyroidism, 23 euthyroid patients receiving treatment with antithyroid drugs and 15 patients with thyrotoxicosis in remission after completing one year's antithyroid treatment. The patients with untreated thyrotoxicosis had significantly higher IL-2R values than the euthyroid patients receiving treatment or those in remission (207 +/- 112 vs 139 +/- 66 and 91 +/- 26 U/ml, P < 0.05 and P < 0.01). The IL-2R values of patients with thyrotoxicosis in remission were, however, significantly lower than those of the 28 healthy subjects (126 +/- 34 U/l; P < 0.01) or the euthyroid patients receiving treatment (P < 0.05). The 18 patients with Hashimoto's thyroiditis had significantly lower serum IL-2R values (70 +/- 39 U/ml) than the healthy controls. These data show that the serum IL-2R level depends on the state of thyroid metabolism and on the activity phase of the thyrotoxicosis. The low serum levels of IL-2R in patients with Hashimoto's thyroiditis could signify a genetically determined decrease in IL-2R production or might be linked with the destruction of thyroid tissue by the chronic autoimmune process.
对55例甲状腺毒症患者（14例男性，41例女性，平均年龄43.5±17岁）、18例桥本甲状腺炎患者（5例男性，13例女性，平均年龄47±15岁）和28名健康受试者（12例男性，16例女性，平均年龄30±10岁）的血清白细胞介素-2受体（IL-2R）浓度进行了比较。甲状腺毒症患者根据疾病的活动度或阶段分为三组：17例未经治疗的显性甲状腺功能亢进患者、23例接受抗甲状腺药物治疗的甲状腺功能正常患者和15例完成一年抗甲状腺治疗后处于缓解期的甲状腺毒症患者。未经治疗的甲状腺毒症患者的IL-2R值显著高于接受治疗的甲状腺功能正常患者或缓解期患者（207±112 vs 139±66和91±26 U/ml，P<0.05和P<0.01）。然而，处于缓解期的甲状腺毒症患者的IL-2R值显著低于28名健康受试者（126±34 U/l；P<0.01）或接受治疗的甲状腺功能正常患者（P<0.05）。18例桥本甲状腺炎患者的血清IL-2R值（70±39 U/ml）显著低于健康对照组。这些数据表明，血清IL-2R水平取决于甲状腺代谢状态和甲状腺毒症的活动阶段。桥本甲状腺炎患者血清IL-2R水平较低可能表明IL-2R产生存在基因决定的减少，或者可能与慢性自身免疫过程对甲状腺组织的破坏有关。
